Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.

about

The Safety of Generic Prescription Drugs in the United States.

P2860

Q48291107-22895474-4EA0-4D5A-97BA-6C6D0F4A2617

P2860

Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.

Item

http://www.wikidata.org/entity/Q40132052

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Patient-relevant outcomes asso ...... porting System: a pilot study.

@en

type

Item

label

Patient-relevant outcomes asso ...... porting System: a pilot study.

@en

prefLabel

Patient-relevant outcomes asso ...... porting System: a pilot study.

@en

P1476

Patient-relevant outcomes asso ...... porting System: a pilot study.

@en

P2093

Jodi B Segal

http://www.w3.org/2001/XMLSchema#string

Sathiya Priya Marimuthu

http://www.w3.org/2001/XMLSchema#string

P2860

The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years

Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.

Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients.

Safety and efficacy of generic drugs with respect to brand formulation.

Web-based patient-reported outcomes in drug safety and risk management: challenges and opportunities?

An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.

Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

P304

437-447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/CER-2017-0006

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sonal Singh

Geetha Iyer

P577

2017-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28686057

http://www.w3.org/2001/XMLSchema#string

Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.

about

P2860

P2860

Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698